Since these pathways both mediate PD-L1 expression and are associated with primary resistance to EGFR-TKI, we conducted this study to identify the key pathway that may impact the inconsistency in the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.